Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Copper Complex Halts Botulinum Neurotoxin Poisoning

By HospiMedica International staff writers
Posted on 12 Jun 2017
A new study describes how a readily available metal salt could provide a new therapy for Botulinum Neurotoxin type A (BoNT/A), the most common and deadly cause of human botulism.

Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. More...
They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.

They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.

“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”

BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.

Related Links:
Scripps Research Institute
Boston University

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.